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The SARS-CoV-2 pandemic has triggered global efforts to develop therapeutics. The main
protease of SARS-CoV-2 (Mpro), critical for viral replication, is a key target for therapeutic
development. An organoselenium drug called ebselen has been demonstrated to have potent
Mpro inhibition and antiviral activity. We have examined the binding modes of ebselen and its
derivative in Mpro via high resolution co-crystallography and investigated their chemical
reactivity via mass spectrometry. Stronger Mpro inhibition than ebselen and potent ability to
rescue infected cells were observed for a number of derivatives. A free selenium atom bound
with cysteine of catalytic dyad has been revealed in crystallographic structures of Mpro with
ebselen and MR6-31-2 suggesting hydrolysis of the enzyme bound organoselenium covalent
adduct and formation of a phenolic by-product, confirmed by mass spectrometry. The target
engagement with selenation mechanism of inhibition suggests wider therapeutic applications
of these compounds against SARS-CoV-2 and other zoonotic beta-corona viruses.
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The recent emergence of severe acute respiratory syndromecoronavirus 2 (SARS-CoV-2) has resulted in a globalpandemic of coronavirus disease 2019 (COVID-19) with
confirmed infection cases of over 140 million and 3 million
fatalities as of April 2021. SARS-CoV-2 is the most devastating
zoonotic coronavirus to infect humans following SARS-CoV-1
and MERS-CoV (Middle East respiratory syndrome) which
emerged in 2002 and 2012, respectively1. Similar to the other
coronaviruses, SARS-CoV-2 primarily infects the respiratory
system and develops critical pneumonia that highly necessitates
ventilatory support and intensive care, particularly in elderly and
immunocompromised individuals2. Whilst there have been tre-
mendous strides forward in the development of vaccines, the
current roll-out is supply and time-limited. Several vaccines have
been developed and approved for mass immunity3. However,
some vaccines need to be stored at cryogenic temperatures that
may not be deployable in developing areas of the world. More-
over, some mutations in SARS-CoV-2 genome may impact the
effectiveness of vaccines to control the virus4,5. These underline
the requirement for the parallel development of therapeutic
options for SARS-CoV-2 treatment.
SARS-CoV-2 is an enveloped, positive-sense, single-stranded
RNA virus with a large genome of about 30,000 nucleotides. The
whole genome of SARS-CoV-2 is 96% identical to a bat cor-
onavirus and closely related to SARS-CoV-1 with 80% sequence
identity6. Two overlapping polyproteins, pp1a and pp1ab, are
encoded by the replicase gene (ORF 1a/1b) that constitutes two-
thirds of the genome. The remainder of the genome encodes for
accessory and structural proteins, such as the spike glycoprotein,
envelope protein, matrix protein and the nucleocapsid
phosphoprotein7. pp1a and pp1ab are proteolytically digested
into 15 non-structural proteins (NSPs) by the two viral proteases.
The 33.8 kDa main protease (Mpro) or NSP5 is responsible for
cleaving polyproteins at 11 cleavage sites giving NSP4-9 and
NSP12-15. The released NSPs form the viral RNA polymerase
complex are involved in replication and transcription of fresh
virus in the host. Due to vital function in SARS-CoV-2 life cycle
and absence of homologous proteins in human, Mpro has been
extensively explored by high-throughput screening of re-
purposed druggable compounds8 and fragments9 to devise
effective inhibitors aimed at arresting the growth of SARS-CoV-2
in host’s cell.
SARS-CoV-2 Mpro is a homodimeric enzyme consisting of
three domains8. The substrate-binding site with a catalytic dyad
of His41 and Cys145 is located between chymotrypsin-like
domains I and picornavirus 3C protease-like domain II. Domain
III plays an important role in Mpro dimerization through a salt-
bridge interaction between protomers. Several inhibitors and
fragments have been co-crystallised and identified to block cat-
alytic cavity8–10.
Ebselen is an organoselenium molecule that can function as a
glutathione peroxidase and peroxiredoxin mimic11. It has been
shown to form a seleno sulphide bond with thiol groups of
cysteine (Cys) on a number of proteins which results in anti-
inflammatory, anti-microbial and neuroprotective effects12–14.
Moreover, ebselen is being investigated in clinical trials as a
potential therapy for stroke, hearing loss and bipolar disorder
with good safety profiles with no adverse effects15–17. Recently,
ebselen was identified in high-throughput screen as a potential
hit of SARS-CoV-2 Mpro inhibitor with an IC50 between 0.67 and
2.1 μΜ8,18. Molecular dynamics simulations suggested that
ebselen is able to bind at two probable sites19. One is at Cys145
within the catalytic cavity through a seleno sulphide bond, and
another is at the dimerization region. However, no experimental
data for the site of its binding in SARS-CoV-2 Mpro has become
available.
In our previous work, we have designed CNS penetrant
ebselen-based derivatives and demonstrated their good neuro-
protective effects and low cytotoxicity in cell-based and mouse
models of motor neuron disease20. Here, ebselen and five deri-
vatives were assessed for their inhibition of SARS-CoV-2 Mpro
and anti-coronaviral activity. Two of these ebselen-based sele-
nium compounds exhibit greater inhibitory effectiveness than
ebselen against Mpro enzyme and SARS-CoV-2 replication. We
show from co-crystallographic studies of Mpro enzyme with
ebselen and another potent compound (MR6-31-2) that these
compounds solely bind at the Mpro catalytic site by donating a
selenium atom, forming a covalent bond and blocking the
histidine-Cys catalytic dyad. We propose that the ebselen-enzyme
drug protein adduct is hydrolysed by the conserved water in
the catalytic pocket. The release of phenol by-product has been
confirmed by mass spectrometry studies of Mpro incubated with
compounds. This intriguing selenation mechanism of inhibition
and direct observation of covalent binding of the selenium atom
together with sub-micromolar antiviral activity provides a
rational for utilising ebselen as potential therapy and improving
selenium-based compounds using the ebselen scaffold for greater
anti-coronaviral activity.
Results
Mpro enzymatic and antiviral activities of ebselen and deriva-
tives. In our previous study, ebselen and some selenium-based
derivatives have were developed as neuroprotective agents in
relation to motor neuron disease20. The co-crystalised structures
of those compounds with superoxide dismutase 1 were proven to
form a selenyl sulphide bond with Cys111 at dimer interface.
Thus, ebselen and derivatives were considered for their reactivity
with Cys145 and their potential for impairing proteolytic activity
of Mpro in an attempt to arrest the growth of SARS-CoV-2. A
fluorescence resonance energy transfer assay was conducted to
evaluate the inhibition level against Mpro enzyme of ebselen and
five other selenium-based derivatives. Figure 1 shows chemical
structures, inhibitory curves against Mpro and the half-maximal
inhibitory concentrations (IC50s) for each of the compounds. The
data clearly demonstrates that these compounds including ebse-
len are potent Mpro inhibitor with sub-micromolar levels of IC50.
Some compounds are twice as effective for Mpro inhibition than
the parent ebselen, especially MR6-7-2 and MR6-18-2. All of
these compounds were also assessed for in vitro antiviral activity
against SARS-CoV-2 infected primate Vero cells. All of the
compounds tested were somewhat superior to ebselen with MR6-
31-2 being nearly three times more effective with an EC50 of 1.8
μM (Fig. 1g, Supplementary Fig. 1 and Supplementary Table 1).
These results indicate clear on-target interaction of these com-
pounds with Mpro with significant inhibitory power for SARS-
CoV-2 and as such potential for development as treatments for
COVID-19 patients.
Structures of Mpro with ebselen and MR6-31-2 reveal selenium
atom bound in catalytic site. The interaction of ebselen and its
derivative with Mpro was directly visualised by co-crystallisation of
organoselenium compounds with Mpro. The structures of ligand-
free and Mpro complexes with ebselen and MR6-31-2 have been
solved at the resolution of 1.6–2.0 Å. The statistics of data col-
lection and structure refinement is summarised in Table 1. All
Mpro structures have the same packing in C2 space group with
only one Mpro protomer found in asymmetric unit. The global
structures of untreated and compound-treated Mpro are almost
identical with the root-mean-square deviations between 0.17 and
0.20 Å (Fig. 2a). The Mpro catalytic site including Cys-histidine
dyad of individual structures are given in Fig. 2b–d. Electron
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density is clearly visible, allowing amino acid residues and water
molecules to be defined accurately. Interestingly, a clear patch of
electron density is observed between Cys145 and His41 in co-
crystallised crystals of Mpro-ebselen and Mpro-MR6-31-2. This
density is too strong to be a water, but the size is too small for
the corresponding complete inhibitors. To identify the origin of
this clear density, anomalous electron density map of selenium
was calculated from diffraction data using X-ray at the wavelength
near selenium absorption edge (0.97 Å). No selenium anomalous
density is observed in ligand-free enzyme (Fig. 2b), but a strong
anomalous density at 3σ is present only at the Cys-histidine cat-
alytic dyad in ligand-treated Mpro structures (Fig. 2c, d). Thus,
selenium atom was modelled into the density with the distances of
2.2 Å away from Cys145 and His41. Calculated B-factor suggest
that the occupancy of selenium in Mpro-ebselen and Mpro-MR6-
31-2 crystals are 60% and 80%, respectively. These data are con-
sistent with ebselen and MR6-31-2 primarily binding at Mpro
catalytic pocket and form a selenyl sulphide bond with Cys145.
There was no density associated with the organic backbone of
either ebselen or MR6-31-2 in the co-crystallographic structures.
The position of the selenium is very similar to that obtained by
molecular docking (Supplementary Fig. 2). As only selenium atom
is observed in the enzyme’s active site, it is the inactivation of Cys
by selenium that results in the inhibition of Mpro activity and viral
replication. Interestingly, selenium binding does not affect the
conformation of surrounding amino acid residues within the
active site. Moreover, a conserved water molecule which is
3.6–4.0 Å away from Nε of His41, forming a hydrogen bond with
the main chain of His164 was observed in all structures
(Fig. 2b–d). The distance between His41 and the conserved water
gets closer in Mpro-ebselen and Mpro-MR6-31-2 structures that is
consistent with its role in hydrolysis of protein-compound adduct.
Fig. 1 Chemical structures, in vitro Mpro inhibition and cell-based antiviral assays of ebselen and five derivatives. In vitro Mpro inhibitory curves of a
ebselen, b MR6-7-2, c MR6-17-1, d MR6-18-4, e MR6-26-2 and f MR6-31-2. Inhibition percentage plots are means of n= 3 measurements obtained over
three independent experiments and error bars representing the standard error of the mean. g IC50s of Mpro inhibition and EC50s of viral replication in Vero
E6 cells. IC50s and EC50s are means (standard error of log(concentration)).
Table 1 Crystallographic data collection and refinement




Space group C2 C2 C2
Cell dimensions
a, b, c (Å) 115.35, 53.61, 44.98 113.20, 53.78, 44.92 114.00,
53.62, 44.54












Rmerge(%) 3.7 (29.5) 3.8 (58.5) 7.5 (107.9)
Rpim(%) 3.5 (26.7) 3.6 (53.3) 6.9 (97.1)
CC1/2 0.999 (0.899) 0.998 (0.699) 0.997 (0.446)
I /σI 13.2 (2.2) 12.4 (1.8) 8.6 (1.6)
Completeness (%) 99.9 (99.9) 99.5 (100.0) 99.9 (99.9)
Redundancy 3.3 (3.4) 3.4 (3.5) 3.3 (3.2)
Refinement
Resolution (Å) 48.49–1.65 48.39–2.05 33.87–1.85
No. reflections 32,461 16,661 21,465
Rwork /Rfree(%) 17.60/18.70 20.10/22.05 22.39/24.90
No. atoms
Protein 2360 2324 2335
Sea 0 1 1
Water 250 88 139
B-factors (Å2)
Protein 15.58 50.12 36.18
Se – 52.68 38.72
Water 37.88 51.39 39.47
R.m.s. deviations
Bond lengths (Å) 0.0104 0.0066 0.0068
Bond angles (°) 1.712 1.489 1.572
Ramachandran plot
Preferred (%) 97.37 97.35 96.69
Allowed (%) 2.30 2.32 3.31
Outliers (%) 0.33 0.33 0
PDB code 7BAJ 7BAK 7BAL
aSelenium occupancy is 0.60 (ebselen) and 0.80 (MR6-31-2).
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According to crystallographic evidence, we noted that ebselen
and selenium-based derivatives have unusual mode of action by
selenation of Mpro catalytic dyad.
LC-MS characterization of salicylanilide by product generated
by hydrolysis of ebselen. Co-crystalised structures of Mpro with
ebselen and MR6-31-2 demonstrated that the compounds inhibits
Mpro by the selenation at Cys145 of catalytic dyad. This evidence
suggests that the compounds may be hydrolysed within Mpro
active site that releases its phenolic by-product (salicylanilide for
ebselen, Fig. 3a). In order to identify the hydrolysis product
derived from Mpro-ebselen adduct, LC/MRM-MS method was
optimized using standard salicylanilide. A representative chro-
matogram from standard salicylanilide (85.2 ng/mL) is shown in
Fig. 3a. Samples obtained from the incubation of ebselen showed
strong peaks at 6.37 min corresponding to salicylanilide (Fig. 3b).
The MS/MS spectrum of molecular ion at m/z 214 showed pro-
duct ions at m/z 121 and m/z 94, which are attributed to the ions
derived from the cleavage of the amide bond (Fig. 3c). To mea-
sure the levels of salicylanilide formed in the incubation, an
8-point calibration line was generated for salicylanilide in bovine
serum albumin (BSA). The measured concentration of salicyla-
nilide in these samples after 240 min was 1.28 ng/ml. The for-
mation of salicylanilide in the incubation of Mpro with ebselen is
time-dependent (Fig. 3d). LC-MS/MS analysis of the tryptic
digest of ebselen-treated human glutathione S-transferase-pi
revealed a Cys-ebselen adduct with a mass addition of 274.996
amu, while no such mass addition was obtained with Cys145 in
Mpro peptide FTIKGSFLNGSCGSVGF (Supplementary Fig. 3).
Discussion
From a chemical mechanism of action perspective, we fully
expected to see the SARS-CoV-2 Mpro drug-adduct 2 from
ebselen 1, through nucleophilic attack of the Cys145 thiolate on
the electrophilic selenium centre as shown in Fig. 4. Unlike other
Mpro covalent inhibitors8,21,22, the organic framework of ebselen
was not present in the co-crystallographic structures with evi-
dence of extrusion of selenium atom from the ebselen core at a
Cys protease active site. We propose that His41 can assist a water-
mediated attack on intermediate adduct 2 in an SNAr type
hydrolysis reaction with intermediate 3 possibly stabilised in a
manner akin to peptide hydrolysis tetrahedral intermediates
within the oxyanion hole of the active site. With increased activity
in the drug-design field in the covalent modification of catalytic
and non-catalytic thiols, there have been several reports of aro-
matic warheads tuned with leaving groups (halides for example)
to enable nucleophilic aromatic substitution, so the SNAr aspect
of the proposed mechanism is with precedent23–25. Based on this
mechanism, we would expect to see the generation of the
hydrolysis product 4. Using liquid chromatography mass spec-
trometry (LCMS) analysis of the SARS-CoV-2 Mpro and com-
parison with a commercial of 4, we were able to show that 4 is
Fig. 2 Crystallographic structures of ligand-free Mpro and the complexes with ebselen and MR6-31-2. a Cartoon representation of superimposed
structures of ligand-free Mpro (magenta), Mpro-ebselen (cyan) and Mpro-MR6-31-2 (green). The Mpro catalytic site is highlighted in a black box and the
global root-mean-square derivations (RMSDs) of the compound-treated structures to ligand-free Mpro are given in blue texts. Close-up views of catalytic
site of b ligand-free Mpro, c Mpro-ebselen and dMpro-MR6-31-2. Electron density (2Fo–Fc) map is shown as grey mesh at 1σ. Anomalous signal of selenium
is shown as purple mesh at 3σ. Selenium atom, conserved water and other waters are shown as orange, blue and red spheres, respectively. The close
contacts below 2.5 Å and hydrogen bonds are shown as yellow and light blue dashes, respectively. The distances are illustrated by black double-headed
arrows.
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Fig. 3 Representative chromatograph for salicylanilide standard and its formation in the incubation of Mpro with ebselen. a The peak at 6.36min
retention time corresponds to salicylanilide standard (85.2 ng/mL). b Salicylanilide was detected in the incubation of Mpro with ebselen. c MS/MS
spectrum shows the characteristic fragments derived from salicylanilide. d Time-course of salicylanilide formation. Bar chart represents means of n= 3
measurements obtained over three independent experiments and error bars representing the standard error of the mean.
Fig. 4 Chemical mechanism for selenation of Mpro cysteine 145 by ebselen. His41 assists a water-mediated attack on intermediate 2 leading to
a hydrolysis reaction akin to peptide hydrolysis leading to the generation of the hydrolysis product 4.
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generated from ebselen by the enzyme in a time-dependent
manner. This provides strong support for our proposed
mechanism for selenation of the SARS-CoV-2 Mpro active site.
We have succeeded in obtaining co-crystallographic structure of
Mpro grown with ebselen and its derivative MR6-31-2, showing
selenium coordinates directly to Cys145 upon hydrolysis of the
organoselenium compounds. The clear target engagement paves
the way for the further development for more effective delivery to
the catalytic Cys and greater inhibition whilst having an acceptable
safety profile. The selectivity for Cys145 and sub-micromolar
potency for Mpro makes a strong case for benzoisoselenazolone to
be integrated into known Mpro inhibitor scaffolds. Though our
study is of clear immediate interest for SARS-CoV-2, it has wider
therapeutic applications of organoselenium compounds by che-
mical mechanism of the selenation of Cys of proteases in other
current zoonotic beta coronaviruses and those that may emerge in
the future.
Methods
Synthesis of compounds. Ebselen was obtained from a commercial supplier
(Sigma-Aldrich). Other lead compounds were produced and purified at Depart-
ment of Chemistry, University of Liverpool. Details of the synthesis of ebselen-
based derivatives have been described in Supplementary methods.
Recombinant SARS-CoV-2 Mpro production. SARS-CoV-2 Mpro gene (GenBank:
MN908947.3, residues 3258-3569) containing modified human rhinovirus 3C
protease (HRV-3C) cleavage site and 6xHis tag (SGVTFQGPHHHHHH) at C-
terminal was cloned into pGEX-6P-1 vector at BamHI and XhoI sites using gene
synthesis and cloning services (GenScript, USA). The plasmid was transformed
into E. Coli strain BL21(DE3) and cultured at 37 °C in 2xYT broth until optical
density at 600 nm reaches 0.8. Mpro expression was induced by the addition of 0.5
mM isopropyl ß-d-1-thiogalactopyranoside followed by the incubation at 37 °C for
5 h. The bacteria pellet was harvested by centrifugation at 5000 × g, 4 °C for 20 min
and then re-suspended in lysis buffer (20 mM Tris pH 7.8, 150 mM NaCl) before
sonicated on ice. Cell lysate was collected by centrifugation at 30,000 × g, 4 °C for
30 min and then loaded onto a 5 mL NiNTA affinity column (HisTrap HP, GE
Healthcare) pre-equilibrated with the lysis buffer. Mpro bound to NiNTA resin was
washed with 100 mL of 5 mM imidazole in lysis buffer and then eluted with a linear
gradient of imidazole from 5 to 500 mM in lysis buffer, 100 mL. The fractions
containing Mpro were pooled together, mixed with recombinant His-tag HRV-3C,
and dialysed against 20 mM Tris pH 7.8, 150 mM NaCl, 1 mM DTT at 4 °C
overnight. The mixture containing Mpro was re-loaded through fresh NiNTA resin
to remove uncleaved protein and HRV-3C. The His-tag cleaved Mpro in the flow-
through was buffer-exchanged to 20 mM Tris pH 8 using Amicon Ultra centrifugal
filter (MWCO. 10 kDa, Merck) and then loaded onto 5 mL Q Sepharose column
(HiTrap Q HP, GE Healthcare). The column was eluted with 100 mL of a linear
gradient from 0 to 200 mM NaCl in 20 mM Tris pH 8. The fractions containing
pure Mpro were buffer-exchanged to 20 mM Tris pH 7.8, 150 mM NaCl for activity
assay and crystallisation or 25 mM ammonium bicarbonate pH 7.5 for LC-MS
analysis. The concentration of Mpro was determined by ultraviolent absorption at
280 nm using a molar extinction coefficient of 32,890 M−1cm−1.
Mpro inhibition activity assay. The inhibition activity assays were performed
using 0.2 μM Mpro, 20 μM substrate and serial-diluted tested inhibitors in 60 μL
reaction buffer consisting of 50 mM Tris pH 7.3, 1 mM EDTA. Firstly, Mpro was
incubated with testing inhibitors at 30 °C for 15 min in reaction buffer. The
reaction was then initiated by the addition of a FRET-based peptide substrate
Mca–AVLQ↓SGFR-K(Dnp)K (GL Biochem), using wavelengths of 320 and 405 nm
for excitation and emission, respectively. Fluorescence intensity was monitored
with an EnVision multimode plate reader (PerkinElmer). Initial rate was obtained
using the data from the first 10 min by linear regression. To exclude inhibitors
possibly acting as aggregators, a detergent-based control was performed by adding
0.01% freshly made-up Triton X-100 to the reaction at the same time. The IC50 was
calculated by plotting the inhibition rate against various concentrations of testing
inhibitor by using a four parameters dose–response curve in GraphPad Prism
8 software. All experiments were performed in triplicate.
Antiviral activity assay. A clinical isolate of SARS-CoV-2 (nCoV-2019BetaCoV/
Wuhan/WIV04/2019) was propagated in Vero E6 cells, and viral titer was deter-
mined by 50% tissue culture infective dose (TCID50) using immunofluorescence
assay. Briefly, Vero E6 cells were fixed with 4% paraformaldehyde and permea-
bilised with 0.5% Triton X-100 before blocked with 5% BSA for 2 h at 25 °C. The
blocked cells were incubated with the primary antibody of polyclonal antibody
against viral nucleocapsid protein of a bat SARS-CoV26 and followed by the second
antibody of Alexa 488-labeled goat anti-rabbit (Abcam). The nuclei were stained
with Hoechst 33258 dye (Beyotime) before visualised by fluorescence microscopy.
For the antiviral assay, pre-seeded Vero E6 cells (5 × 104 cells/well) were pre-
treated with the different concentration of compound for 1 h and the virus was
subsequently added (MOI of 0.01) to allow infection for 1 h. At 24-h post infection,
the cell supernatant was collected and extracted viral RNA using MiniBEST Viral
RNA/DNA Extraction Kit (Tanaka, #RR047A). Reverse transcription was con-
ducted using PrimeScript RT Reagent Kit with gDNA eraser (Tanaka, #RR047A) to
prepare cDNA template. qRT-PCR analysis was carried out on StepOne Plus Real-
time PCR (Applied Biosystem) with TB Green Premix Ex Taq II (Tanaka,
#RR820A). Receptor binding domain (RBD) of spike gene was amplified by PCR
from the cDNA template with primers: RBD-F: 5′-GCTCCATGGCCTAATATTA
CAAACTTGTGCC3′; RBD-R: 5′-TGCTCTAGACTCAAGTGTCTGTGGATCAC-
3′, cloned into pMT/BiP/V5-His vector (Invitrogen) and used as the standard
plasmid. A standard curve was generated by the determination of copy numbers
from serially dilutions (103–109 copies) of the standard plasmid. The primers used
for quantitative PCR were RBD-qF1: 5′-CAATGGTTTAACAGGCACAGG-3′ and
RBD-qR1: 5′-CTCAAGTGTCTGTGGATCACG-3′26. PCR amplification was per-
formed as follows: 95 °C for 5 min followed by 40 cycles consisting of 95 °C for 15 s,
54 °C for 15 s, 72 °C for 30 s. For cytotoxicity assays, pre-seeded Vero E6 cells were
treated with appropriate concentrations of compound. After 24 h, the relative
numbers of surviving cells were measured by the CCK8 (Beyotime) assay in
accordance with the manufacturer’s instructions. All experiments were performed
in triplicate, and all the infection experiments were performed at biosafety level-3.
Crystallisation and structure determination. Ebselen and other compounds were
prepared as 250 mM stocks in DMSO. 0.1 mM purified Mpro was incubated with 1
mM compound at 4 °C overnight before concentrated to 5–15 mg/mL protein.
Hanging crystallisation drops were set by mixing of 3 μL of Mpro, 2.4 μL of
reservoir solution (200 mM ammonium chloride, 5% glycerol and 16–20% poly-
ethylene glycol (PEG) molecular weight 3350) and 0.6 μL of 1/2560 diluted micro-
seed stock. Micro-seed stock was prepared by crushing Mpro crystals obtained from
an initial hit (well A9 of JCSG+ screen: 200 mM NH4Cl, 20% PEG3350, Molecular
Dimensions) with glass seed beads (Hampton Research). The crystallisation drops
were placed against 300 μL corresponding reservoir at 19 °C allowing vapour dif-
fusion. Plate crystals of Mpro appeared among precipitation within a week. The
crystals were cryo-protected in 25% glycerol in reservoir solution before snap-
frozen in liquid nitrogen. X-ray diffraction experiments were carried out at 100 K
using 0.9795 Å beam on I04 beamline of Diamond Light Source, UK. Identification
of selenium in active site was made by anomalous x-ray diffraction measurement in
the same crystal using 0.9795 Å wavelength at 3.0 Å resolution. The data were
integrated by using Xia2 DIALS27 and scaled by using Aimless in CCP4 suite28.
Phase problem was solved by molecular replacement with MOLREP29 in
CCP4 suite using a SARS-CoV-2 Mpro structure (PDB: 6Y2E) as an initial model.
Structure models were edited manually in COOT30 and refined by using Refmac531
in CCP4 suite. Geometry and quality of final models were validated by using
MolProbity32. All molecular structures were visualised using Pymol software.
Liquid chromatography mass spectrometry (LCMS). 10 mg/mL Mpro in 25 mM
ammonium bicarbonate pH 7.5 (20 µL) was incubated with 1 mM ebselen at 37 °C
for 0, 2, and 4 h. At the end of incubation, 2.5 mM acetaminophen (10 µL) was
added as an internal standard to normalize extraction. Then, loading and com-
pounds of interest were extracted by adding ice-cold acetone (250 µL). Standard
curve was constructed by spiking salicylanilide (concentration range: 0.1–0.8 µM)
into 10 mg/mL BSA solution. After centrifugation at 16,100 × g for 20 min, the
extracts were transferred to clean tubes and evaporated in a Speed Vac and
reconstituted in 50 µL 30% ACN/0.1% formic acid. A total of 10 µL of samples and
standards were analysed immediately by a QTRAP 5500 mass spectrometer (AB
Sciex) coupled with an Ultimate 3000 HPLC system (Dionex, ThermoScientific)
and a Kinetex C18 column (2.6 µM, C18, 50 mm × 2.1 mm, Phenomenex). The MS
experiments were conducted using electrospray ionization with positive ion
detection. A gradient programme of acetonitrile (5% for 1 min; 5–95% over 5 min;
95% for 2 min; 95–5% over 0.1 min; 5% for 4 min) in 0.1% formic acid (v/v) was
applied at a flow rate of 300 µL/min. The multiple reaction monitoring transitions
for each analyte were as following: salicylanilide 214.2/121.1 and 214.2/95; acet-
aminophen, 152.1/108.1; other MS parameters, such as voltage potential and col-
lision energy were optimized to achieve great sensitivity. Data acquisition and
quantification were performed using Analyst 1.5 software, Multi-Quant 3.0 (AB
Sciex) and Microsoft Excel.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data are provided with this paper. Other data are available from the
corresponding authors upon reasonable request. Crystal structures of ligand-free MPro
and Mpro with ebselen and MR6-31-4 have been deposited in the Protein Data Bank
under accession codes: 7BAJ, 7BAK and 7BAL, respectively.
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